A nurse who started a charity from a granny flat in her parent’s backyard to reduce hospital waste has taken out one of the Australian nursing profession’s most prestigious honours.
Brisbane’s Claire Lane MACN was today named the 2022 winner of the Health Minister’s Award for Nursing Trailblazers, a national award recognising nurses whose leadership has led to innovative solutions addressing key challenges facing our health and aged care systems.
Claire received the award for her work with Save our Supplies, a for-purpose organisation that collects excess clean usable medical supplies from hospitals.
Working with Rotary, they redirect the supplies to areas of need, including developing nations, war-torn areas like Ukraine and Flood impact regions of Australia.
The announcement was made at the Australian College of Nursing (ACN) National Nursing Forum in Darwin by Assistant Minister for Health and Aged Care Ged Kearney.
ACN CEO Adjunct Professor Kylie Ward FACN congratulated Claire on becoming the fourth nurse – and third successive from Queensland – to win the Health Minister’s Award for Nursing Trailblazers.
“Claire is an exceptional woman and nurse who has used her leadership, expertise and passion for social impact – characteristics our profession prides itself on – to make the world and future a better place,” Adjunct Professor Ward said.
“She not only created an innovative solution to address one of the biggest challenges facing our healthcare systems, but has gone above and beyond to use it to improve the health of people across the world.
“She exemplifies the mission of the Health Minister’s Award for Nursing Trailblazers, showcasing to Australians the leading role nurses’ skills and expertise play in shaping the lives of those we care for.
Assistant Minister Ged Kearney noted the honour she felt as a nurse to announce the recipient of the Health Minister’s Award for Nursing Trailblazers. She also reflected on “how proud she was to have been a nurse” and that she wanted “every single nurse to be proud of what you do every day for all Australians”.
-
Sharing the same goals in value-based procurement
Value-based procurement (VBP) is a journey, not a sprint. It’s about putting the patient at the centre of quality affordable healthcare through changes in procurement practices for medical technologies. Patient outcomes drive value and sustainability, not just price. The bigger picture indicates that VBP will create system cost saving through benefitting patients, rather than trying to attain the reverse – a win-win outcome.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy.
Australian Health Journal met with 3 speakers at the recent ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
